Transposon-activated POU5F1B promotes colorectal cancer growth and metastasis

Laia Simó‐Riudalbas, Sandra Offner, Evarist Planet, Julien Duc, Laurence Abrami, Sagane Dind, Alexandre Coudray, Mairene Coto‐Llerena, Caner Ercan, Salvatore Piscuoglio, Claus L. Andersen, Jesper B. Bramsen, Didier TronoNature Communications 2022 · DOI

TL;DR

This study identifies a novel oncogene, POU5F1B, activated by transposable elements (TEs) in colorectal cancer (CRC). POU5F1B expression is a strong negative prognostic marker and drives tumor growth and metastasis, offering potential new therapeutic targets.

What Problem Does This Paper Address?

Colorectal cancer (CRC) remains a significant health challenge, particularly due to a lack of early diagnostic markers and effective treatments for advanced stages. While transposable elements (TEs) are known to play roles in genome evolution and can be aberrantly activated in cancer, their specific contribution to oncogenesis, especially through the production of novel gene transcripts, is not fully understood. This paper addresses the need to identify and characterize such TE-driven cancer-specific transcripts and to elucidate their functional impact on CRC progression.

Methods

The researchers employed a multi-omic approach, combining RNA sequencing (RNA-seq) of CRC patient samples with bioinformatic analyses to identify transposable element-driven chimeric gene transcripts (TcGTs). They utilized techniques such as 5'-rapid amplification of cDNA ends (RACE) to confirm transcript structures, and various in vitro and in vivo models (cell culture, xenotransplantation in immunodeficient mice) to assess the functional impact of POU5F1B. Protein interactome studies (AP-MS) and proteomic analyses (SILAC coupled with LC-MS/MS) were used to understand POU5F1B's molecular mechanisms. Chromatin immunoprecipitation (ChIP-PCR) and CRISPRi/CRISPRa experiments were used to investigate the regulatory mechanisms behind TcGT activation.

Datasets

The study utilized several datasets:

  • SYSCOL cohort: A primary dataset of 286 CRC patients with matched normal colon tissue, used for identifying TcGTs and correlating them with clinical outcomes.
  • GSE50760 dataset: An independent dataset of 18 CRC patients, used to validate findings regarding LTR66-POU5F1B TcGT expression in primary tumors and liver metastases.
  • TCGA (The Cancer Genome Atlas) database: Used for analyzing POU5F1B TcGT prevalence across various cancer types and for ATAC-seq data to assess chromatin accessibility.
  • GTEx (Genotype-Tissue Expression) dataset: Used to assess POU5F1B expression in normal human tissues.
  • EGAD00001000725 repository: Provided RNA-seq data from cancer cell lines.
  • Publicly available data from Jäger et al. (2015): Used for long-range chromatin interaction data.

Key Insights and Ideas

  • TEs as drivers of novel oncogenes: The study highlights how TEs, specifically primate-specific endogenous retroviral promoters, can aberrantly activate previously uncharacterized genes like POU5F1B, turning them into potent oncogenes.
  • POU5F1B as a prognostic marker: The expression level of the LTR66-POU5F1B TcGT is a strong negative prognostic indicator for CRC patients, correlating with shorter overall and relapse-free survival.
  • POU5F1B's distinct localization and function: Unlike its paralog OCT4, which is nuclear, POU5F1B localizes to the cytoplasm and cell membranes, associating with protein kinases and cytoskeletal molecules. This localization is crucial for its pro-oncogenic functions.
  • Mechanism of activation: The LTR66-POU5F1B TcGT is activated by an intronic enhancer region, which is characterized by open chromatin in various human cancers, suggesting a broader role for this regulatory mechanism.
  • POU5F1B's role in metastasis: POU5F1B not only promotes tumor growth but also significantly enhances the metastatic potential of CRC cells, particularly in the liver.

Key Results

  • Identification of POU5F1B TcGTs: The study identified POU5F1B-containing TcGTs, primarily driven by the LTR66 endogenous retroviral promoter, in a significant proportion (65%) of CRC tumors, with very low expression in normal tissues.
  • Prognostic significance: Increased LTR66-POU5F1B expression was associated with significantly worse overall survival (HR=2.52, P=0.0007) and relapse-free survival (HR=8.61, P=0.038) in stage II/III CRC patients.
  • Functional impact on CRC cells: Overexpression of POU5F1B in CRC cell lines led to increased colony formation and proliferation. In vivo studies showed that POU5F1B-overexpressing cells formed larger tumors and exhibited significantly more liver metastases. Conversely, POU5F1B knockdown impaired tumor growth and metastasis.
  • Mechanism of action: POU5F1B interacts with signaling molecules and cytoskeletal components, influencing intracellular signaling and the release of trans-acting factors that promote cell growth and adhesion.
  • Broader cancer relevance: POU5F1B TcGTs were detected in other human cancers, including prostate, uterus, breast, lung, and stomach cancers, suggesting a potentially widespread role in oncogenesis.

Limitations and Future Work

  • TCGA dataset discrepancy: The study noted that the prognostic value of POU5F1B was not significant in the TCGA dataset, which they hypothesize could be due to differences in patient populations and therapeutic regimens compared to the SYSCOL cohort. This warrants further investigation.
  • Mechanism of TcGT induction: While an intronic enhancer was identified as regulating LTR66-POU5F1B expression, the precise mechanisms driving its aberrant activation (e.g., trans-acting influences or cis-acting mutations) are not fully elucidated and could be a focus for future research.
  • Therapeutic targeting: The authors suggest that POU5F1B itself, or the trans-acting mediators it releases, could be targets for novel cancer therapies. Further research is needed to explore the efficacy and safety of such therapeutic strategies.
  • Physiological role of POU5F1B: The physiological role of POU5F1B in normal tissues is still largely unknown, despite its low expression. Understanding its normal function could provide further insights into its oncogenic activities.

Summary updated

Abstract

The treatment of colorectal cancer (CRC) is an unmet medical need in absence of early diagnosis. Here, upon characterizing cancer-specific transposable element-driven transpochimeric gene transcripts (TcGTs) produced by this tumor in the SYSCOL cohort, we find that expression of the hominid-restricted retrogene POU5F1B through aberrant activation of a primate-specific endogenous retroviral promoter is a strong negative prognostic biomarker. Correlating this observation, we demonstrate that POU5F1B fosters the proliferation and metastatic potential of CRC cells. We further determine that POU5F1B, in spite of its phylogenetic relationship with the POU5F1/OCT4 transcription factor, is a membrane-enriched protein that associates with protein kinases and known targets or interactors as well as with cytoskeleton-related molecules, and induces intracellular signaling events and the release of trans-acting factors involved in cell growth and cell adhesion. As POU5F1B is an apparently non-essential gene only lowly expressed in normal tissues, and as POU5F1B-containing TcGTs are detected in other tumors besides CRC, our data provide interesting leads for the development of cancer therapies.
BibTeX
@inproceedings{simoriudalbas2022transposon,
  author = {Laia Simó‐Riudalbas and Sandra Offner and Evarist Planet and Julien Duc and Laurence Abrami and Sagane Dind and Alexandre Coudray and Mairene Coto‐Llerena and Caner Ercan and Salvatore Piscuoglio and Claus L. Andersen and Jesper B. Bramsen and Didier Trono},
  title = {{Transposon-activated POU5F1B promotes colorectal cancer growth and metastasis}},
  booktitle = {Nature Communications},
  year = {2022},
  doi = {10.1038/s41467-022-32649-7},
}
Figure